Haemorheological Effects of Losartan and Enalapril in Patients with Renal Parenchymal Disease and Hypertension
Total Page:16
File Type:pdf, Size:1020Kb
Journal of Human Hypertension (2000) 14, 305–309 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh ORIGINAL ARTICLE Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension BI Shand Department of Nephrology, Christchurch Hospital, Christchurch, New Zealand The objective of this study was to compare the effects an increase in blood cell deformability. In patients tak- of the angiotensin II (ang II) antagonist, losartan and the ing losartan, the increase in blood cell deformability did angiotensin-converting enzyme inhibitor (ACEI), enalap- not result in a decrease in mean whole blood viscosity ril on haemorheology. Twenty-nine patients with renal due to a concomitant, significant increase in mean parenchymal disease and hypertension were enrolled in plasma viscosity (P Ͻ 0.01). In contrast, the improved the prospective, open, parallel study that involved a 14- cell deformability in patients treated with enalapril day washout period followed by a 120-day treatment resulted in a small and statistically insignificant mean ;0.06 ؍ period. Patients were allocated randomly to receive decrease in mean whole blood viscosity (P ؊0.15 mPa sec). The mechanism of the؍ or enalapril 2.5– change (15 ؍ either losartan 50–100 mg/day (n to achieve blood pressure control increase in blood cell deformability and the rise in (14 ؍ mg/day (n 10 Ͻ140/90 mm Hg. Blood pressure, haemorheology profile plasma viscosity associated with losartan remain and plasma fibrinogen concentration were measured unclear. It is possible but unproven that the improve- after the washout phase and after 2, 10, 60, and 120 days ment in intrinsic blood cell rheology with losartan and of treatment. The data were analysed using ANOVA with enalapril may be the result of changes in cation trans- repeated measures. Twenty-seven patients completed port systems and/or the consequence of the protective the study. Treatment with both losartan and enalapril antioxidant properties of drug metabolites. was associated with a significant decrease (P Ͻ 0.05) in Journal of Human Hypertension (2000) 14, 305–309 relative high shear rate whole blood viscosity, indicating Keywords: haemorheology; angiotensin II antagonists; angiotensin-converting enzyme inhibitors; erythrocyte deformability; plasma viscosity; renal disease Introduction decreased RBC aggregation.3,7,8 The mechanism(s) responsible for the improvements in intrinsic RBC The flow properties of blood (haemorheology) are a rheology remain poorly understood but are possibly major determinant of vascular resistance and blood 1 linked to decreased angiotensin II (ang II) pro- pressure. In order for an antihypertensive agent to duction3 or, indirectly, to changes in sympathetic have maximum blood pressure lowering potential it tone and haemodynamics.7 The recent development is important that determinants of haemorheology are of the ang II receptor antagonists, of which losartan not adversely affected. There is now considerable is the prototype, provide a means of studying the evidence that with the exception of the thiazide physiological actions of ang II specifically.9 Two diuretics, all major classes of antihypertensive drugs small studies, including one from our research are associated with beneficial haemorheological 10,11 changes.2,3 These changes include haemodilution group have shown that long-term treatment with with ␣ and  receptor antagonists,4,5 or improve- losartan was associated with a small but clinically ments in red blood cell (RBC) deformability induced significant decrease in whole blood viscosity. by calcium channel antagonists.6 The aim of the present study was to compare the Within the last decade several studies have shown haemorheological effects of losartan and enalapril that angiotensin-converting enzyme inhibitors and to determine whether a decrease in either ang (ACEls) improve haemorheology by a combination II activity or concentration had similar effects on of actions that include haemodilution secondary to determinants of whole blood viscosity. The study vasodilatation, increased RBC deformability and was carried out in patients with renal parenchymal disease and hypertension as this patient group is known to have an increased incidence of haemo- 8,12 Correspondence: Dr Brett Shand, Lipid and Diabetes Research rheological abnormalities. Group, Christchurch Hospital, Private Bag 4710, Christchurch, New Zealand Received 7 September 1999; revised 28 December 1999; accepted 10 February 2000 Haemorheology and inhibition of angiotensin II BI Shand 306 Patients and methods and plasma viscosity measurements, respectively. Plasma fibrinogen concentration was determined by Patients the heat precipitation method.16 Twenty-nine patients (15 males) mean age 45 ± 13 An index of blood cell deformability was obtained years (range 21–75 years) with hypertension, renal by determining the relative whole blood viscosity at parenchymal disease and stable renal function high shear rate. This was calculated as whole blood ± viscosity at 200 per sec standardised to 0.45 haema- (mean plasma creatinine 0.11 0.04 mmol/l; range 17 0.03–0.18 mmol/l) were enrolled in the study. tocrit divided by plasma viscosity. Patients taking diuretics or requiring more than one antihypertensive agent were excluded from the Statistical analysis study. This number of patients provided the study with a power of 95% at the 0.05 significance level Changes in indices over time were determined using assuming a decrease in mean high shear rate whole analysis of variance with repeated measures and blood viscosity of 0.16 mPa/sec with a standard Dunnett multiple comparisons test (GraphPad TM ± deviation of 0.12 mPa/sec. These values were selec- Instat ). Results are given as mean standard devi- ted on the basis of data from an earlier study on the ation. Associations between indices were determ- rheological effects of enalapril8 that was carried in ined by calculating the Pearson correlation coef- patients with renal parenchymal disease. ficient. The effect of the two drugs on plasma viscosity was compared using the Wilcoxin rank sum test. Study design The study was an open, comparative design and was Results approved by the local ethics committee. Following There was no significant difference in age (losartan enrollment, the patient’s antihypertensive therapy 48 ± 13 years; enalapril 43 ± 12 year) or plasma crea- was stopped for 14 days. Blood pressure was meas- tinine concentration (losartan 0.10 ± 0.05 mmol/l; ured midway and at the end of this washout period. enalapril 0.11 ± 0.04 mmol/l) in the two treatment Following the washout period patients were ran- groups. Two patients were withdrawn from the domised to receive either losartan (50–100 mg/day) study, one patient on losartan for inadequate blood or enalapril (2.5–10 mg/day) for 120 days. The dos- pressure control and the other patient on enalapril, age of either drug was titrated during the study to Ͻ who developed cough. The clinical and haemorheo- achieve blood pressure control of 140/90 mm Hg logical data from the remaining 27 patients (14 losar- in the sitting position. Measurement of blood press- tan, 13 enalapril) are summarised in Tables 1 and ure and collection of venous blood samples for hae- 2 respectively. matology, haemorheology (EDTA anticoagulated) Blood pressure was reasonably well controlled and plasma creatinine concentration were carried with either drug. The dosage of the antihypertensive out at day 0 (end of washout period) and after 2, 10, medication was increased during the study in 5 60 and 120 days of treatment. A 24-h urine sample patients on losartan and in 8 patients taking enalap- was also collected at day 0 and 120 to determine ril. Mean plasma creatinine concentration and mean endogenous creatinine clearance. creatinine clearance did not change significantly with either drug. Methods Mean haematocrit and mean whole blood vis- cosity at both high and low shear rates did not Sitting blood pressure was measured by the same change significantly with either drug. No patient operator in triplicate using a mercury sphygmoman- ometer and the median measurement recorded. Table 1 Time-related changes in clinical parameters in patients Plasma creatinine concentration was measured ± using the picrate acid method (Hitachi treated with losartan or enalapril (mean s.d.) autoanalyser). Blood pressure (mm Hg) Plasma Creatinine Creatinine clearance prior to the study was creatinine clearance 13 2 assessed using the formula of Cockroft and Gault Systolic Diastolic (mmol/l) (ml/sec 1.73 m ) while creatinine clearance during the study was measured by a 24-h urine collection. Haematology Losartan indices were determined using an automatic cell Day 0 153 (18) 100 (13) 0.11 (0.05) 1.88 (0.32) counter (Coulter STKS, Coulter Electronics, Luton, Day 2 140 (21)** 90 (11)** 0.11 (0.05) – UK). Whole blood viscosity at 37°C at the patient’s Day 10 135 (18)** 89 (7)** 0.11 (0.05) – Day 60 137 (16)** 90 (13)** 0.11 (0.06) – haematocrit was measured at shear rates of 200 per Day 120 138 (16)** 88 (8)** 0.11 (0.06) 1.90 (0.32) sec and 20 per sec in a programmable rheometer (Brookfield Engineering, MA, USA) according to re- Enalapril commended standard procedures14 and the data Day 0 141 (14) 96 (13) 0.11 (0.04) 1.82 (0.21) analysed using Rheocalc software. Plasma viscosity Day 2 136 (13) 83 (11)** 0.11 (0.05) – ° Day 10 136 (12) 86 (12)** 0.12 (0.05) – at 37 C was measured using a capillary viscometer Day 60 137 (13)